Altis is accelerating clinical trials with AI endpoints so that drug developers can get the best new treatment to patients sooner.
Altis Labs has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in September 2026.
Altis Labs's investors include Fusion Fund, OrbiMed, Lumira Ventures, Benchstrength, Creative Destruction Lab.
Altis Labs is headquartered in Toronto, Canada.
Altis is accelerating clinical trials with AI endpoints so that drug developers can get the best new treatment to patients sooner.
Altis Labs is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Altis Labs — Funding & Investors." VCBacked, September 17, 2026, https://www.vcbacked.co/company/altis-labs. Accessed November 17, 2026.
VCBacked. (2026). Altis Labs — Funding & Investors. Retrieved November 17, 2026, from https://www.vcbacked.co/company/altis-labs
{{cite web |title=Altis Labs — Funding & Investors |url=https://www.vcbacked.co/company/altis-labs |website=VCBacked |access-date=November 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Altis Labs? Request a listing update